Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
3 "Nam Seok Ham"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Corrigendum
IBD
Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye, on behalf of the Korean Association for the Study of Intestinal Diseases
Intest Res 2023;21(2):273-273.   Published online April 28, 2023
DOI: https://doi.org/10.5217/ir.2021.00173.e
Corrects: Intest Res 2023;21(1):137
PDFPubReaderePub
  • 1,996 View
  • 145 Download
Close layer
Original Article
IBD
Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye, on behalf of the Korean Association for the Study of Intestinal Diseases
Intest Res 2023;21(1):137-147.   Published online July 12, 2022
DOI: https://doi.org/10.5217/ir.2021.00173
Correction in: Intest Res 2023;21(2):273
AbstractAbstract PDFPubReaderePub
Background/Aims
We investigated the real-world effectiveness and safety of ustekinumab (UST) as induction treatment for Koreans with Crohn’s disease (CD).
Methods
CD patients who started UST were prospectively enrolled from 4 hospitals in Korea. All enrolled patients received intravenous UST infusion at week 0 and subcutaneous UST injection at week 8. Clinical outcomes were assessed using Crohn’s Disease Activity Index (CDAI) scores at weeks 8 and 20 among patients with active disease (CDAI ≥150) at baseline. Clinical remission was defined as a CDAI <150, and clinical response was defined as a reduction in CDAI ≥70 points from baseline. Safety and factors associated with clinical remission at week 20 were also analyzed.
Results
Sixty-five patients were enrolled between January 2019 and December 2020. Among 49 patients with active disease at baseline (CDAI ≥150), clinical remission and clinical response at week 8 were achieved in 26 (53.1%) and 30 (61.2%) patients, respectively. At week 20, 27 (55.1%) and 35 (71.4%) patients achieved clinical remission and clinical response, respectively. Twenty-seven patients (41.5%) experienced adverse events, with serious adverse events in 3 patients (4.6%). One patient (1.5%) stopped UST therapy due to poor response. Underweight (body mass index <18.5 kg/m2) (odds ratio [OR], 0.085; 95% confidence interval [CI], 0.014–0.498; P=0.006) and elevated C-reactive protein at baseline (OR, 0.133; 95% CI, 0.022–0.823; P=0.030) were inversely associated with clinical remission at week 20.
Conclusions
UST was effective and well-tolerated as induction therapy for Korean patients with CD.

Citations

Citations to this article as recorded by  
  • Long-term real-world data of ustekinumab in Crohn’s disease: the Stockholm ustekinumab study
    Francesca Bello, Samer Muhsen, Haider Sabhan, Alexandra Borin, Fredrik Johansson, Charlotte Höög, Ole Forsberg, Christina Wennerström, Charlotte Söderman, Mikael Lördal, Sven Almer
    Therapeutic Advances in Gastroenterology.2024;[Epub]     CrossRef
  • Approach to loss of response to advanced therapies in inflammatory bowel disease
    Nikil Vootukuru, Abhinav Vasudevan
    World Journal of Gastroenterology.2024; 30(22): 2902.     CrossRef
  • One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn’s Disease: The K-STAR Study
    Chang Kyun Lee, Won Moon, Jaeyoung Chun, Eun Soo Kim, Hyung Wook Kim, Hyuk Yoon, Hyun Soo Kim, Yoo Jin Lee, Chang Hwan Choi, Yunho Jung, Sung Chul Park, Geun Am Song, Jong Hun Lee, Eun Suk Jung, Youngdoe Kim, Su Young Jung, Jong Min Choi, Byong Duk Ye
    Inflammatory Bowel Diseases.2024;[Epub]     CrossRef
  • Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
    Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye
    Intestinal Research.2023; 21(2): 273.     CrossRef
  • 4,441 View
  • 443 Download
  • 5 Web of Science
  • 4 Crossref
Close layer
Review
IBD
Endoscopic molecular imaging in inflammatory bowel disease
Nam Seok Ham, Seung-Jae Myung
Intest Res 2021;19(1):33-44.   Published online April 20, 2020
DOI: https://doi.org/10.5217/ir.2019.09175
AbstractAbstract PDFPubReaderePub
Molecular imaging is a technique for imaging the processes occurring in a living body at a molecular level in real-time, combining molecular cell biology with advanced imaging technologies using molecular probes and fluorescence. Gastrointestinal endoscopic molecular imaging shows great promise for improving the identification of neoplasms, providing characterization for patient stratification and assessing the response to molecular targeted therapy. In inflammatory bowel disease, endoscopic molecular imaging can be used to assess disease severity and predict therapeutic response and prognosis. Endoscopic molecular imaging is also able to visualize dysplasia in the presence of background inflammation. Several preclinical and clinical trials have evaluated endoscopic molecular imaging; however, this area is just beginning to evolve, and many issues have not been solved yet. In the future, it is expected that endoscopic molecular imaging will be of increasing interest among clinicians as a new technology for the identification and evaluation of colorectal neoplasm and colitis-associated cancer.

Citations

Citations to this article as recorded by  
  • Feasibility of moxifloxacin and proflavine dual fluorescence imaging for detecting gastrointestinal neoplastic lesions: A prospective study
    Kwangwoo Nam, Noseong Park, Seunghun Lee, Suil Jeon, Jungbin Lee, Seung‐Mo Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Byong Duk Ye, Jeong‐Sik Byeon, Suk‐Kyun Yang, Jeong Hoon Lee, Do Hoon Kim, Ki Hean Kim, Seung‐Jae Myung
    Lasers in Surgery and Medicine.2023; 55(4): 378.     CrossRef
  • Fluorescence Molecular Targeting of Colon Cancer to Visualize the Invisible
    Thinzar M. Lwin, Michael A. Turner, Siamak Amirfakhri, Hiroto Nishino, Robert M. Hoffman, Michael Bouvet
    Cells.2022; 11(2): 249.     CrossRef
  • Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice
    Kyeong Ok Kim
    Clinical Endoscopy.2022; 55(4): 480.     CrossRef
  • Active Assessment of Inflammatory Bowel Disease
    金良 肖
    Advances in Clinical Medicine.2022; 12(12): 11023.     CrossRef
  • Differentiating between Intestinal Tuberculosis and Crohn’s Disease May Be Complicated by Multidrug-resistant Mycobacterium tuberculosis
    Seung Wook Hong, Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang
    The Ewha Medical Journal.2021; 44(3): 93.     CrossRef
  • Biomolecular imaging of colorectal tumor lesions using a FITC-labeled scFv-Cκ fragment antibody
    Hyung Il Kim, Jinhyeon Kim, Hyori Kim, Hyeri Lee, Yong Sik Yoon, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Suk-Kyun Yang, Sun Young Kim, Seung-Jae Myung
    Scientific Reports.2021;[Epub]     CrossRef
  • Is Multidrug-resistant Extrapulmonary Tuberculosis Important? If So, What Is Our Strategy?
    Seong-Eun Kim
    The Ewha Medical Journal.2021; 44(4): 148.     CrossRef
  • 6,837 View
  • 217 Download
  • 6 Web of Science
  • 7 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP